Asep Medical Holdings Inc. announced that it has signed a Feasibility Study Agreement with Bohai Biomedical Technology Development Co. Ltd., (Bohai Biomedical). The agreement permits Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient.

The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an oral rinse product. The peptide technology has been in-licenced from the University of British Columbia (UBC) to Asep Inc.'s subsidiary, ABT Innovations. The agreement with Bohai Biomedical was signed on October 3, 2022, and the study is set to commence in the coming weeks with several thousand participants.

The peptide mouthwash has already undergone testing at the UBC Department of Dentistry under the supervision of Dr. Ya Shen and Dr. Markus Haapasalo in close collaboration with the Asep Inc. team. The preliminary results look promising in fighting difficult-to-treat oral biofilms, which are at the heart of a USD 36.2 billion global dental market.